Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients

Table 1

General characteristics of the enrolled patients ().

Variable	Healthy controls (no. 60)	NAFLD population (no. 90)	NAFLD treated patients (no. 60)	Not treated NAFLD patients (no. 30)
Age (y)
Sex (M/F)	30/30	48/42	29/31	19/11
Weight (kg)
BMI (kg/m^2)
WHtR
Systolic blood pressure (mmHg)
Controlled attenuation parameters (dB/m)
AST (IU/l)
ALT (IU/l)
γGT (IU/l)
FPG (mg/dl)
Insulinemia (μU/ml)
HOMA-IR
TCH (mg/dl)
TG (mg/dl)
LDL (mg/dl)
Vitamin D (ng/ml)
CRP (μg/mg)
Ferritin (μg/l)
TNF-α (pg/ml)
EGFR (ng/ml)
CD-44 (ng/ml)
IL-18 (pg/ml)
IGF-II (pg/ml)
IL-22 (pg/ml)
TGF-β (pg/ml)
MMP-2 (ng/ml)
FIB-4
NFS
Stiffness (kPa)
Endocan (pg/ml)
HMGB-1 (pg/ml)
TBARS (nmol/μg)

NAFLD: nonalcoholic fatty liver disease; BMI: body mass index; WHtR: waist-to-height ratio; AST: aspartate aminotransferase; ALT: alanine aminotransferase; γGT: gamma glutamyl transpeptidase; FPG: fasting plasma glucose; HOMA-IR: homeostatic model assessment for insulin resistance; TCH: total cholesterol; TG: triglycerides; LDL: low-density lipoprotein; CRP: C reactive protein; TNF-α: tumor necrosis factor-alpha; EGFR: epidermal growth factor receptor; CD-44: cluster of differentiation 44; IL-18: interleukin-18; IGF-II: insulin growth factor-II; IL-22: interleukin-22; TGF-β: transforming growth factor-beta; MMP-2: metalloproteinase-2; HMGB-1: high mobility group box-1; TBARS: thiobarbituric acid reactive substances.